1. Tabit, C.E.; Chung, W.B.; Hamburg, N.M.; Vita, J.A. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev. Endocr. Metab. Disord. 2010, 11, 61–74. [CrossRef] [PubMed]
2. Vaisman, B.L.; Andrews, K.L.; Khong, S.M.; Wood, K.C.; Moore, X.L.; Fu, Y.; Kepka-Lenhart, D.M.; Morris Jr, S.M.; Remaley, A.T.; Chin-Dusting, J.P. Selective endothelial overexpression of arginase II induces endothelial dysfunction and hypertension and enhances atherosclerosis in mice. PLoS ONE 2012, 7, e39487. [CrossRef] [PubMed]
3. Sharma, S.; Singh, M.; Sharma, P.L. Mechanism of attenuation of diabetes mellitus and hypercholesterolemia induced vascular endothelial dysfunction by protein tyrosine phosphatase inhibition. Vascul. Pharmacol. 2011, 54, 80–87. [CrossRef]
4. Goon, P.K.Y.; Lip, G.Y.H.; Boos, C.J.; Stonelake, P.S.; Blann, A.D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006, 8, 79–88. [CrossRef]
5. Lefer, A.M. Endothelial dysfunction as a trigger for ischemia-reperfusion injury. J. Thromb. 1997, 4, 63–65. [CrossRef]
6. Maniatis, N.A.; Orfanos, S.E. The endothelium in acute lung injury/acute respiratory distress syndrome. Curr. Opin. Crit. Care 2008, 14, 22–30. [CrossRef]
7. Annuk, M.; Zilmer, M.; Fellstrom, B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int. Suppl. 2003, 84, S50–S53. [CrossRef] [PubMed]
8. Murdaca, G.; Colombo, B.M.; Cagnati, P.; Gulli, R.; Spano, F.; Puppo, F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224, 309–317. [CrossRef]
9. Bijl, M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth. J. Med. 2003, 61, 273–277. [PubMed]
10. Thijssen, D.H.; Black, M.A.; Pyke, K.E.; Padilla, J.; Atkinson, G.; Harris, R.A.; Parker, B.; Widlansky, M.E.; Tschakovsky, M.E.; Green, D.J. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H2–H12. [CrossRef] [PubMed]
11. Tremblay, J.C.; Pyke, K.E. Flow-mediated dilation stimulated by sustained increases in shear stress: A useful tool for assessing endothelial function in humans? Am. J. Physiol. Heart Circ. Physiol. 2018, 314, H508–H520. [CrossRef]
12. Becker, B.F.; Chappell, D.; Jacob, M. Endothelial glycocalyx and coronary vascular permeability: The fringe benefit. Basic Res. Cardiol. 2010, 105, 687–701. [CrossRef]
13. Luft, J.H. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. Fed. Proc. 1966, 25, 1773–1783.
14. Rehm, M.; Zahler, S.; Lötsch, M.; Welsch, U.; Conzen, P.; Jacob, M.; Becker, B.F. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology 2004, 100, 1211–1223. [CrossRef]
15. Okada, H.; Takemura, G.; Suzuki, K.; Oda, K.; Takada, C.; Hotta, Y.; Miyazaki, N.; Tsujimoto, A.; Muraki, I.; Ando, Y.; et al. Three-dimensional ultrastructure of capillary endothelial glycocalyx under normal and experimental endotoxemic conditions. Crit. Care 2017, 21, 261. [CrossRef]
16. Ando, Y.; Okada, H.; Takemura, G.; Suzuki, K.; Takada, C.; Tomita, H.; Zaikokuji, R.; Hotta, Y.; Miyazaki, N.; Yano, H.; et al. Brain-specific ultrastructure of capillary endothelial glycocalyx and its possible contribution for blood brain barrier. Sci. Rep. 2018, 8, 17523. [CrossRef]
17. Inagawa, R.; Okada, H.; Takemura, G.; Suzuki, K.; Takada, C.; Yano, H.; Ando, Y.; Usui, T.; Hotta, Y.; Miyazaki, N.; et al. Ultrastructural alteration of pulmonary capillary endothelial glycocalyx during endotoxemia. Chest 2018, 154, 317–325. [CrossRef]
18. Lee, W.L.; Slutsky, A.S. Sepsis and endothelial permeability. N. Engl. J. Med. 2010, 363, 689–691. [CrossRef]
19. Woodcock, T.E.; Woodcock, T.M. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy. Br. J. Anaesth. 2012, 108, 384–394. [CrossRef]
20. Chelazzi, C.; Villa, G.; Mancinelli, P.; De Gaudio, A.R.; Adembri, C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit. Care 2015, 19, 26. [CrossRef]
21. Paulus, P.; Jennewein, C.; Zacharowski, K. Biomarkers of endothelial dysfunction: Can they help us deciphering systemic inflammation and sepsis? Biomarkers 2011, 16, S11–S21. [CrossRef]
22. Salmon, A.H.; Satchell, S.C. Endothelial glycocalyx dysfunction in disease: Albuminuria and increased microvascular permeability. J. Pathol. 2012, 226, 562–574. [CrossRef]
23. Li, L.; Ly, M.; Linhardt, R.J. Proteoglycan sequence. Mol. Biosyst. 2012, 8, 1613–1625. [CrossRef]
24. Rehm, M.; Bruegger, D.; Christ, F.; Conzen, P.; Thiel, M.; Jacob, M.; Chappell, D.; Stoeckelhubar, M.; Welsch, U.; Reichart, B.; et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007, 116, 1896–1906. [CrossRef]
25. Puskarich, M.A.; Cornelius, D.C.; Tharp, J.; Nandi, U.; Jones, A.E. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. J. Crit. Care 2016, 36, 125–129. [CrossRef]
26. Ostrowski, S.R.; Haase, N.; Müller, R.B.; Møller, M.H.; Pott, F.C.; Perner, A.; Johansson, P.I. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: A prospective study. Crit. Care 2015, 19, 191. [CrossRef]
27. Arthur, A.; McCall, P.J.; Jolly, L.; Kinsella, J.; Kirk, A.; Shelley, B.G. Endothelial glycocalyx layer shedding following lung resection. Biomark. Med. 2016, 10, 1033–1038. [CrossRef]
28. Murphy, L.S.; Wickersham, N.; McNeil, J.B.; Shaver, C.M.; May, A.K.; Bastarache, J.A.; Ware, L.B. Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunction. Ann. Intensiv. Care 2017, 7, 102. [CrossRef]
29. Henrich, M.; Gruss, M.; Weigand, M.A. Sepsis-induced degradation of endothelial glycocalix. Sci. World J. 2010, 10, 917–923. [CrossRef]
30. Kim, Y.H.; Nijst, P.; Kiefer, K.; Tang, W.H. Endothelial glycocalyx as biomarker for cardiovascular diseases: Mechanistic and clinical implications. Curr. Heart Fail. Rep. 2017, 14, 117–126. [CrossRef]
31. Libório, A.B.; Braz, M.B.M.; Seguro, A.C.; Meneses, G.C.; de Oliveira Neves, F.M.; Pedrosa, D.C.; de Góes Cavalcanti, L.P.; Martins, A.M.C.; de Francesco Daher, E. Endothelial glycocalyx damage is associated with leptospirosis acute kidney injury. Am. J. Trop. Med. Hyg. 2015, 92, 611–616. [CrossRef]
32. De Oliveira Neves, F.M.; Meneses, G.C.; Sousa, N.E.A.; Parahyba, M.C.; Martins, A.M.C.; Libório, A.B. Syndecan-1 in acute decompensated heart failure—Association with renal function and mortality. Circ. J. 2015, 79, 1511–1519. [CrossRef]
33. Padberg, J.S.; Wiesinger, A.; di Marco, G.S.; Reuter, S.; Grabner, A.; Kentrup, D.; Lukasz, A.; Oberleithner, H.; Pavenstädt, H.; Brand, M.; et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014, 234, 335–343. [CrossRef]
34. Grundmann, S.; Fink, K.; Rabadzhieva, L.; Bourgeois, N.; Schwab, T.; Moser, M.; Bode, C.; Busch, H.J. Perturbation of the endothelial glycocalyx in post cardiac arrest syndrome. Resuscitation 2012, 83, 715–720. [CrossRef]
35. Muller, R.B.; Ostrowski, S.R.; Haase, N.; Wetterslev, J.; Perner, A.; Johansson, P.I. Markers of endothelial damage and coagulation impairment in patients with severe sepsis resuscitated with hydroxyethyl starch 130/0.42 vs Ringer acetate. J. Crit. Care. 2016, 32, 16–20. [CrossRef]
36. Ostrowski, S.R.; Gaini, S.; Pedersen, C.; Johansson, P.I. Sympathoadrenal activation and endothelial damage in patients with varying degrees of acute infectious disease: An observational study. J. Crit. Care 2015, 30, 90–96. [CrossRef]
37. Sloop, G.D.; Weidman, J.J.; St Cyr, J.A. Perspective: Interesterified triglycerides, the recent increase in deaths from heart disease, and elevated blood viscosity. Ther. Adv. Cardiovasc. Dis. 2018, 12, 23–28. [CrossRef]
38. Florian, J.A.; Kosky, J.R.; Ainslie, K.; Pang, Z.; Dull, R.O.; Tarbell, J.M. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ. Res. 2003, 93, e136–e142. [CrossRef]
39. Mochizuki, S.; Vink, H.; Hiramatsu, O.; Kajita, T.; Shigeto, F.; Spaan, J.A.; Kajiya, F. Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H722–H726. [CrossRef]
40. Thi, M.M.; Tarbell, J.M.; Weinbaum, S.; Spray, D.C. The role of the glycocalyx in reorganization of the actin cytoskeleton under fluid shear stress: A “bumper-car” model. Proc. Natl. Acad. Sci. USA 2004, 101, 16483–16488. [CrossRef]
41. Arisaka, T.; Mitsumata, M.; Kawasumi, M.; Tohjima, T.; Hirose, S.; Yoshida, Y. Effects of shear stress on glycosaminoglycan synthesis in vascular endothelial cells. Ann. N. Y. Acad. Sci. 1995, 748, 543–554. [CrossRef]
42. Gouverneur, M.; Spaan, J.A.; Pannekoek, H.; Fontijn, R.D.; Vink, H. Fluid shear stress stimulates incorporation of hyaluronan into endothelial cell glycocalyx. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, H458–H452. [CrossRef]
43. Zeng, Y.; Tarbell, J M. The adaptive remodeling of endothelial glycocalyx in response to fluid shear stress. PLoS ONE 2014, 9, e86249.
44. Huo, Y.; Kassab, G.S. Effect of compliance and hematocrit on wall shear stress in a model of the entire coronary arterial tree. J. Appl. Physiol. 2009, 107, 500–505. [CrossRef]
45. Chang, E.; Harley, C.B. Telomere length and replicative aging in human vascular tissues. Proc. Natl. Acad. Sci. USA. 1995, 92, 11190–11194. [CrossRef]
46. Stanford, K.I.; Bishop, J.R.; Foley, E.M.; Gonzales, J.C.; Niesman, I.R.; Witztum, J.L.; Esko, J.D. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Invest. 2009, 119, 3236–3245. [CrossRef]
47. Fuki, I.V.; Kuhn, K.M.; Lomazov, I.R.; Rothman, V.L.; Tuszynski, G.P.; Iozzo, R.V.; Swenson, T.L.; Fisher, E.A.; Williams, K.J. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 1997, 100, 1611–1622. [CrossRef]
48. Zeng, B.J.; Mortimer, B.C.; Martins, I.J.; Seydel, U.; Redgrave, T.G. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J. Lipid Res. 1998, 39, 845–860.
49. Yu, K.C.; Chen, W.; Cooper, A.D. LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice. J. Clin. Invest. 2001, 107, 1387–1394. [CrossRef]
50. Meyer, M.E.; Williams, K.J. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts. Biochem. J. 2000, 351, 607–612.
51. Cortés, V.; Amigo, L.; Donoso, K.; Valencia, I.; Quiñones, V.; Zanlungo, S.; Brandan, E.; Rigotti, A. Adenovirus- mediated hepatic syndecan-1 overexpression induces hepatocyte proliferation and hyperlipidaemia in mice. Liver Int. 2007, 27, 569–581. [CrossRef]
52. Sherr, C.J.; DePinho, R.A. Cellular senescence: Mitotic clock or culture shock? Cell 2000, 102, 407–410. [CrossRef]
53. Constantinescu, A.A.; Vink, H.; Spaan, J.A. Elevated capillary tube hematocrit reflects degradation of endothelial cell glycocalyx by oxidized LDL. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1051–H1057. [CrossRef]
54. Nieuwdorp, M.; Mooij, H.L.; Kroon, J.; Atasever, B.; Spaan, J.A.; Ince, C.; Holleman, F.; Diamant, M.; Heine, R.J.; Hoekstra, J.B.; et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006, 55, 1127–1132. [CrossRef]
55. Nieuwdorp, M.; van Haeften, T.W.; Gouverneur, M.C.; Mooij, H.L.; van Lieshout, M.H.; Levi, M.; Meijers, J.C.; Holleman, F.; Hoekstra, J.B.; Vink, H.; et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006, 55, 480–486. [CrossRef] [PubMed]
56. Broekhuizen, L.N.; Lemkes, B.A.; Mooij, H.L.; Meuwese, M.C.; Verberne, H.; Holleman, F.; Schlingemann, R.O.; Nieuwdorp, M.; Stroes, E.S.; Vink, H. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53, 2646–2655. [CrossRef] [PubMed]